The Combination of Zerumbone and 5-FU: A Significant Therapeutic Strategy in Sensitizing Colorectal Cancer Cells to Treatment

被引:4
|
作者
Dehghan, Razieh [1 ]
Bahreini, Fatemeh [1 ]
Najafi, Rezvan [1 ]
Saidijam, Massoud [1 ]
Amini, Razieh [1 ]
机构
[1] Hamadan Univ Med Sci, Res Ctr Mol Med, Hamadan, Hamadan, Iran
关键词
EPITHELIAL-MESENCHYMAL TRANSITION; UP-REGULATION; SIGNALING PATHWAY; 5-FLUOROURACIL; APOPTOSIS; SURVIVIN; CHEMOSENSITIZATION; CHEMORESISTANCE; SENSITIVITY; SUPPRESSION;
D O I
10.1155/2021/6635874
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objectives. Chemotherapy is considered to be essential in the treatment of patients with colorectal cancer (CRC), but drug resistance reduces its efficacy. Many patients with advanced CRC eventually show resistance to 5-fluorouracil (5-FU) therapy. Synergistic and potentiating effects of combination therapy, using herbal and chemical drugs, can improve patients' response. Zerumbone (ZER), which is derived from ginger, has been studied for its growth inhibitory function in various types of cancer. Methods. The cytotoxic effects of ZER and 5-FU alone and their combination, on the SW48 and HCT-116 cells, were examined, using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT). The mRNA and protein levels of beta-catenin, survivin, and vimentin were measured in treated CRC cells, using qRT-PCR and western blot. Colony formation assay, scratch test, and flow cytometry were performed to detect the changes of proliferation, migration, and apoptosis. Key Findings. In HCT-116- and SW48-treated cells, the proliferation, the gene and protein expression levels of the markers, the migration, the colony formation, and the survival rates were all significantly reduced compared to the control groups, and the sharpest decline was observed in the 5-FU+ZER treatment groups. Conclusions. Combination therapy has shown promising results in CRC cells, especially in drug-resistant cells.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] TREATMENT OF METASTATIC COLORECTAL-CARCINOMA WITH CISPLATIN AND 5-FU
    SHEPARD, KV
    FAINTUCH, J
    BITRAN, JD
    SWEET, DL
    ROBIN, E
    LEVIN, B
    CANCER TREATMENT REPORTS, 1985, 69 (01): : 123 - 124
  • [42] Comparison of 5-FU versus capecitabine in combination with mitomycin or cisplatin in the treatment of anal cancer
    Yu, Irene S.
    Cheung, Winson Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [43] Methotrexate (MTX) and 5-fluorouracil (5-FU) in advanced colorectal cancer patients previously treated with adjuvant 5-FU
    Pronzato, P
    Vaira, F
    Viganni, A
    Losardo, P
    Bertelli, G
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 760 - 760
  • [44] 5-FLUOROURACIL (5-FU) COMBINED WITH LEUCOVORIN (LV) IN PATIENTS WITH ADVANCED 5-FU RESISTANT COLORECTAL-CANCER
    VANGROENINGEN, CJ
    PETERS, GJ
    PINEDO, HM
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 202 - 202
  • [45] Effect of resveratrol and in combination with 5-FU on murine liver cancer
    Wu, Sheng-Li
    Sun, Zhong-Jie
    Yu, Liang
    Meng, Ke-Wei
    Qin, Xing-Lei
    Pan, Cheng-En
    WORLD JOURNAL OF GASTROENTEROLOGY, 2004, 10 (20) : 3048 - 3052
  • [46] Effect of resveratrol and in combination with 5-FU on murine liver cancer
    Sheng-Li Wu Zhong-Jie Sun Liang Yu Ke-Wei Meng Xing-Lei Qin Cheng-En Pan Department of Hepatobiliary Surgery
    World Journal of Gastroenterology, 2004, (20) : 3048 - 3052
  • [47] Molecular and phenotypic characterization of 5-FU resistant colorectal cancer cells: toward enrichment of cancer stem cells
    Amirhesam Babajnai
    Saeed Rahmani
    Mohammad Jamal Asadi
    Elmira Gheytanchi
    Glavizh Adibhesami
    Faezeh Vakhshiteh
    Zahra Madjd
    Cancer Cell International, 25 (1)
  • [48] A systematic review of the safety profile of bolus, continuous infusion of 5-fu and capecitabine in combination with oxaliplatin in the treatment of colorectal cancer patients
    Chiara, B.
    Zichi, C.
    Di Maio, M.
    Sonetto, C.
    Brizzi, M. P.
    Scagliotti, G. V.
    Tampellini, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [49] A phase II trial of gefitinib in combination with 5-FU/LV/irinotecan in patients with colorectal cancer.
    Redlinger, M
    Kramer, A
    Flaherty, K
    Sun, W
    Haller, D
    O'Dwyer, PJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 310S - 310S
  • [50] Combination of ZD55-MnSOD therapy with 5-FU enhances antitumor efficacy in colorectal cancer
    Zhang, Yiqun
    Qin, Xinyu
    Zhang, Yanhong
    Zhao, Lili
    Wang, Yigang
    Liu, Xinyuan
    Yao, Liqing
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2008, 134 (02) : 219 - 226